AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29936703 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 126
Study 29936703 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 126
Study 29936703 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 126
Study 27278474 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment brochure
Number of subjects: 60000
Study 27278474 — intervention group
Group type: COMPARATOR
Intervention: Postcard
Number of subjects: 60000
Study 27278474 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted postcard (includes 'Men' in headline)
Number of subjects: 60000
Study 27278474 — intervention group
Group type: COMPARATOR
Intervention: Generic postcard
Number of subjects: 60000
Study 27278474 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted postcard (for women)
Number of subjects: 60000
Study 27278474 — intervention group
Group type: COMPARATOR
Intervention: Generic postcard (for women)
Number of subjects: 60000
Study 25014648 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track rehabilitation protocol
Number of subjects: 20
Study 25014648 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocol
Number of subjects: 20
Study 23174399 — intervention group
Group type: EXPERIMENTAL
Intervention: Epimacular brachytherapy (EMBT)
Number of subjects: 494
Study 23174399 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (control)
Number of subjects: 494
Study 22025377 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 28
Study 22025377 — intervention group
Group type: COMPARATOR
Intervention: Normal Control Group
Number of subjects: 28
Study 22025377 — intervention group
Group type: COMPARATOR
Intervention: MI-Untrained Group
Number of subjects: 28
Study 18499008 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco chop
Number of subjects: 60
Study 18499008 — intervention group
Group type: COMPARATOR
Intervention: Divide and conquer
Number of subjects: 60
Study 18499008 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16575739 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (200 mg on day 1, followed by 100 mg/day for 13 days)
Number of subjects: 350
Study 16575739 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (200 mg on day 1, followed by 100 mg/day for 13 days)
Number of subjects: 350
Study 16575739 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 350
Study 16575739 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 350
Study 16575739 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole and Fluconazole
Number of subjects: 350
Study 12676389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter
Number of subjects: 90
Study 12676389 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E(2) tablets
Number of subjects: 90
Study 10739742 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (0.2%, 0.4%)
Number of subjects: 30
Study 10739742 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-retinoic acid
Number of subjects: 30
Study 10739742 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 30
Study 10739742 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline
Number of subjects: 30
Study 9163863 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA-ME (microemulsion formulation)
Number of subjects: 22
Study 9163863 — intervention group
Group type: COMPARATOR
Intervention: CyA-GC (corn oil-based gel capsule)
Number of subjects: 22
Study 1546124 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg/day
Number of subjects: 268
Study 1546124 — intervention group
Group type: COMPARATOR
Intervention: Toloxatone 1000 mg/day
Number of subjects: 268
Study 3096181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate therapy (variable doses based on initial arterial pH)
Number of subjects: 21
Study 3096181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium bicarbonate therapy)
Number of subjects: 21
Study 29109363 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.033 mg/kg/day Norditropin® (somatropin)
Number of subjects: 51
Study 29109363 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.066 mg/kg/day Norditropin® (somatropin)
Number of subjects: 51
Study 29109363 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 0.033 mg/kg/day and 0.066 mg/kg/day
Number of subjects: 51
Study 27298411 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (epirubicin, cisplatin, and fluorouracil)
Number of subjects: 330
Study 23831181 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful life events measured using the Geriatric Life Events Scale (GALES)
Number of subjects: 144
Study 23831181 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed with the Short - Geriatric Depression Scale (S-GDS)
Number of subjects: 144
Study 23831181 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful life events
Number of subjects: 144
Study 23831181 — intervention group
Group type: EXPERIMENTAL
Intervention: Females and persons with worse health
Number of subjects: 144
Study 22302518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 261
Study 22302518 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 261
Study 20138067 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg PO)
Number of subjects: 21
Study 20138067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20138067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat (Naltrexone)
Number of subjects: 21
Study 20138067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat (Placebo)
Number of subjects: 21
Study 20138067 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Fat (Placebo)
Number of subjects: 21
Study 18541949 — intervention group
Group type: EXPERIMENTAL
Intervention: Early delivery and advances in supportive management
Number of subjects: 16252
Study 18541949 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver disorders unique to pregnancy
Number of subjects: 16252
Study 18541949 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia, HELLP syndrome, acute fatty liver of pregnancy
Number of subjects: 16252
Study 18541949 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver test abnormalities
Number of subjects: 16252
Study 19242554 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/day loading dose for 5 days, followed by 4.8 g/day maintenance)
Number of subjects: 40
Study 19242554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent number of placebo capsules)
Number of subjects: 40
Study 19242554 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 40
Study 19242554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15880338 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness
Number of subjects: 3029
Study 15880338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 3029
Study 11716330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective LIMA angiography using a 5 Fr Judkins JL‐3.5 catheter with cuff inflation
Number of subjects: 110
Study 11716330 — intervention group
Group type: COMPARATOR
Intervention: Nonselective LIMA angiography using a 5 Fr Judkins JL‐3.5 catheter without cuff inflation
Number of subjects: 110
Study 9931883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal active charcoal-mitomycin C therapy (MMC‐CH)
Number of subjects: 64
Study 9931883 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection with MMC‐CH therapy
Number of subjects: 64
Study 9931883 — intervention group
Group type: COMPARATOR
Intervention: Palliative resection without cytoreductive surgery
Number of subjects: 64
Study 8072048 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental acupuncture treatment
Number of subjects: 150
Study 8072048 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture treatment
Number of subjects: 150
Study 8072048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and placebo)
Number of subjects: 150
Study 8072048 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report outcomes
Number of subjects: 150
Study 3384243 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F Judkins catheters (Group A)
Number of subjects: 60
Study 3384243 — intervention group
Group type: EXPERIMENTAL
Intervention: 5F Amplatz catheters (Group B)
Number of subjects: 60
Study 3384243 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial artery occlusion (Group B)
Number of subjects: 60
Study 30760751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of oxytocin (OT)
Number of subjects: 0
Study 30760751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29914523 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training with ankle dorsiflexion assistance (Robotic Group, n=9)
Number of subjects: 19
Study 29914523 — intervention group
Group type: COMPARATOR
Intervention: Sham Group (passive AFO, n=10)
Number of subjects: 19
Study 27798022 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Acceptance and Commitment Therapy (PACT)
Number of subjects: 66
Study 27798022 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 66
Study 24589084 — intervention group
Group type: EXPERIMENTAL
Intervention: FEIBA prophylaxis (85 ± 15 U kg(‐1) every other day)
Number of subjects: 36
Study 24589084 — intervention group
Group type: EXPERIMENTAL
Intervention: FEIBA prophylaxis
Number of subjects: 36
Study 24589084 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 36
Study 22123270 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 30 mg tablet (Acupan®)
Number of subjects: 12
Study 18485252 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of pure natural honey during concomitant chemotherapy and radiotherapy
Number of subjects: 40
Study 18485252 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemotherapy and radiotherapy without honey (Control)
Number of subjects: 40
Study 18485252 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of pure natural honey
Number of subjects: 40
Study 17502629 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression care manager working with primary care physicians to provide algorithm-based care
Number of subjects: 1226
Study 17502629 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices
Number of subjects: 1226
Study 15916064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics Intervention Program (EIP)
Number of subjects: 172
Study 15916064 — intervention group
Group type: COMPARATOR
Intervention: Non-EIP group
Number of subjects: 172
Study 11994554 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with APSTD
Number of subjects: 0
Study 11994554 — intervention group
Group type: COMPARATOR
Intervention: Patients without APSTD
Number of subjects: 0
Study 11721378 — intervention group
Group type: EXPERIMENTAL
Intervention: Leunase 6,000 KU/m2, continuous intravenous injection every day for 8 times
Number of subjects: 20
Study 11721378 — intervention group
Group type: COMPARATOR
Intervention: Leunase 6,000 KU/m2, continuous intravenous injection every other day for 8 times
Number of subjects: 20
Study 7585846 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg as a 1-hour i.v. infusion every 24 hours)
Number of subjects: 18
Study 7585846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 500 mg every 3 hours (six times daily) for 3 days
Number of subjects: 18
Study 7585846 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1,000 mg TID for 3 days
Number of subjects: 18
Study 1702340 — intervention group
Group type: EXPERIMENTAL
Intervention: Curbicin (from pumpkin seeds and dwarf palm plants)
Number of subjects: 53
Study 1702340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 158142 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 34
Study 158142 — intervention group
Group type: COMPARATOR
Intervention: Suggestion
Number of subjects: 34
Study 30896062 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff Vision-assisted colonoscopy (EVAC)
Number of subjects: 360
Study 30896062 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 360
Study 28750935 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir 400 mg plus rilpivirine 600 mg (4-week group)
Number of subjects: 309
Study 28750935 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir 600 mg plus rilpivirine 900 mg (8-week group)
Number of subjects: 309
Study 28750935 — intervention group
Group type: COMPARATOR
Intervention: Oral cabotegravir plus abacavir-lamivudine (oral treatment group)
Number of subjects: 309
Study 28750935 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection-site reactions (all groups)
Number of subjects: 309
Study 28750935 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events (intramuscular groups)
Number of subjects: 309
Study 28750935 — intervention group
Group type: COMPARATOR
Intervention: Serious adverse events (oral treatment group)
Number of subjects: 309
Study 25700386 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal multiple micronutrient supplementation
Number of subjects: 841
Study 25700386 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid supplements (Control)
Number of subjects: 841
Study 23727969 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss program
Number of subjects: 0
Study 22112328 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic fetal movement counting from pregnancy week 28
Number of subjects: 1123
Study 22112328 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (routine fetal movement counting discouraged)
Number of subjects: 1123
Study 19184686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock prescriptions
Number of subjects: 144
Study 19184686 — intervention group
Group type: COMPARATOR
Intervention: Reading a description of the regimen
Number of subjects: 144
Study 17678657 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable 2-channel peroneal nerve stimulator
Number of subjects: 29
Study 17678657 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking device (ankle-foot orthosis, orthopedic shoes, or no device)
Number of subjects: 29
Study 15140331 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 0
Study 15140331 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 0
Study 15140331 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 0
Study 15140331 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 0
Study 11956353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 3 kcal min(‐1)
Number of subjects: 8
Study 11956353 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal glucose infusion at 1 kcal min(‐1)
Number of subjects: 8
Study 11956353 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 8
Study 9589821 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 0.1% cream pretreatment
Number of subjects: 82
Study 9589821 — intervention group
Group type: COMPARATOR
Intervention: Testosterone transdermal delivery (TTD) without pretreatment
Number of subjects: 82
Study 9589821 — intervention group
Group type: COMPARATOR
Intervention: Inactive occlusive dressing (control)
Number of subjects: 82
Study 8028511 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.03 mg.kg ideal body weight‐1.d‐1)
Number of subjects: 10
Study 8028511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2662431 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 alpha‐OH‐D3) 1.0 microgram/day
Number of subjects: 140
Study 2662431 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 alpha‐OH‐D3) 2.0 micrograms/day
Number of subjects: 140
Study 2662431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 2662431 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 alpha‐OH‐D3)
Number of subjects: 140
Study 241366 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diazepam (0.3 mg/kg)
Number of subjects: 62
Study 241366 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. flunitrazepam (0.03 mg/kg) combined with pethidine (1 mg/kg)
Number of subjects: 62
Study 241366 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. droperidol (5 mg) combined with fentanyl (0.2 mg)
Number of subjects: 62
Study 241366 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. diazepam (0.3 mg/kg) combined with pethidine (1 mg/kg)
Number of subjects: 62
Study 30810968 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser tattoo removal
Number of subjects: 89
Study 30810968 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (control group)
Number of subjects: 89
Study 30933244 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF)
Number of subjects: 275686
Study 30933244 — intervention group
Group type: COMPARATOR
Intervention: Non-IVF (control)
Number of subjects: 275686
Study 27768119 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 88
Study 27768119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 25844610 — intervention group
Group type: EXPERIMENTAL
Intervention: Own Make-up
Number of subjects: 27
Study 25844610 — intervention group
Group type: COMPARATOR
Intervention: Control Make-up
Number of subjects: 27
Study 25844610 — intervention group
Group type: EXPERIMENTAL
Intervention: No Make-up
Number of subjects: 27
Study 22775982 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Mounted Display (HMD)
Number of subjects: 0
Study 22775982 — intervention group
Group type: COMPARATOR
Intervention: Three Screen Display (TSD)
Number of subjects: 0
Study 20947493 — intervention group
Group type: EXPERIMENTAL
Intervention: distributed constraint‐induced therapy (dCIT)
Number of subjects: 66
Study 20947493 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral arm training (BAT)
Number of subjects: 66
Study 20947493 — intervention group
Group type: COMPARATOR
Intervention: control treatment (CT)
Number of subjects: 66
Study 19934630 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual medical care and community weight-management/fitness resources plus a brief intervention highlighting benefits of activity independent of weight-management
Number of subjects: 26
Study 19934630 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care and community weight-management/fitness resources
Number of subjects: 26
Study 17309447 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid infusion for 2 hours
Number of subjects: 9
Study 17309447 — intervention group
Group type: COMPARATOR
Intervention: Control infusion (Glycerol)
Number of subjects: 9
Study 15517669 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sling placed at the mid-urethra without tension
Number of subjects: 48
Study 15517669 — intervention group
Group type: COMPARATOR
Intervention: Conventional suburethral sling
Number of subjects: 48
Study 11677469 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal tumor ablation (TTA)
Number of subjects: 65
Study 11677469 — intervention group
Group type: COMPARATOR
Intervention: Expandable metal stent insertion
Number of subjects: 65
Study 9825553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 47
Study 9825553 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block
Number of subjects: 47
Study 9825553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bass
Number of subjects: 47
Study 9825553 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study 8572855 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric left ventricular hypertrophy
Number of subjects: 94
Study 8572855 — intervention group
Group type: COMPARATOR
Intervention: Normal left ventricular anatomy
Number of subjects: 94
Study 8572855 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric left ventricular remodeling
Number of subjects: 94
Study 8572855 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric left ventricular hypertrophy
Number of subjects: 94
Study 2569194 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dextropropoxyphene napsylat (DP) daily for 16 days
Number of subjects: 10
Study 2569194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 64951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (intramuscular injection)
Number of subjects: 88
Study 64951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (intravenous injection)
Number of subjects: 88
Study 30721655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 9361
Study 30721655 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 9361
Study 28353144 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily for 2 months)
Number of subjects: 50
Study 28353144 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (40 mg for 2 weeks per month for 2 months)
Number of subjects: 50
Study 25560319 — intervention group
Group type: EXPERIMENTAL
Intervention: Health IT tool intervention (n = 1,143)
Number of subjects: 3655
Study 25560319 — intervention group
Group type: EXPERIMENTAL
Intervention: Health IT tool intervention (n = 486 with elevated LDL)
Number of subjects: 3655
Study 25560319 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 703)
Number of subjects: 3655
Study 25560319 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up safety monitoring
Number of subjects: 3655
Study 23738545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (1 individual session and 11 group sessions)
Number of subjects: 405
Study 23738545 — intervention group
Group type: COMPARATOR
Intervention: Individual support
Number of subjects: 405